KLRK1 and acute myeloid leukemia: Speculating that the failure of NKG2D blocking to decrease killing was a consequence of the low NKG2D ligand expression on Molm-13 (Figure S11D), we performed a series of blocking experiments with neutralizing monoclonal antibodies using eleven different AML cell lines.